Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KPTI | US
0.00
0.35%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
19/09/2024
0.74
0.74
0.76
0.73
Karyopharm Therapeutics Inc. a commercial-stage pharmaceutical company discovers develops and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers develops and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies including multiple myeloma endometrial cancer myelofibrosis and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms as well as verdinexor KPT-9274 and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor eltanexor and KPT-9274 for the treatment and/or prevention of human oncology indications as well as verdinexor for the diagnosis treatment and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton Massachusetts.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
77.5%1 month
64.0%3 months
71.4%6 months
78.2%-
-
12.05
-1.48
0.91
-1.85
0.95
-0.15
-130.61M
92.15M
92.15M
-
-65.72
-
13.90
-891.05
31.83
15.14
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.11
Range1M
0.16
Range3M
0.47
Rel. volume
0.97
Price X volume
335.50K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Benitec Biopharma Limited | BNTC | Drug Manufacturers-Specialty & Generic | 8.625 | 86.99M | 3.17% | n/a | 3.08% |
INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 1.86 | 85.12M | 0.00% | n/a | 41.98% |
Silver Spike Investment Corp. Common Stock | SSIC | Drug Manufacturers-Specialty & Generic | 11.6 | 72.09M | 0.96% | 12.64 | 0.00% |
SCYNEXIS Inc | SCYX | Drug Manufacturers-Specialty & Generic | 1.63 | 61.71M | 3.82% | n/a | 25.73% |
Eagle Pharmaceuticals Inc | EGRX | Drug Manufacturers-Specialty & Generic | 4.27 | 55.33M | -0.23% | 5.07 | 27.85% |
Qilian International Holding Group Limited | QLI | Drug Manufacturers-Specialty & Generic | 8.08 | 48.23M | 1.00% | n/a | 1.35% |
DURECT Corporation | DRRX | Drug Manufacturers-Specialty & Generic | 1.37 | 42.52M | 1.48% | n/a | 318.92% |
Provectus Biopharmaceuticals Inc | PVCT | Drug Manufacturers-Specialty & Generic | 0.0899 | 37.75M | 1.01% | n/a | 0.00% |
Cannex Capital Holdings Inc | ARRXF | Drug Manufacturers-Specialty & Generic | 0.1318 | 33.72M | n/a | 0.50% | |
India Globalization Capital Inc | IGC | Drug Manufacturers-Specialty & Generic | 0.3487 | 26.37M | 2.56% | n/a | 4.33% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Culp Inc | CULP | Textile Manufacturing | 6.35 | 79.31M | 5.31% | n/a | 11.29% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 5.78 | 62.58M | -6.47% | n/a | 54.96% |
ILAG | ILAG | Building Products & Equipment | 1.04 | 18.78M | 13.06% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.02 | 12.43M | -7.27% | n/a | 16.03% |
The Dixie Group Inc | DXYN | Textile Manufacturing | 0.737 | 11.34M | 3.80% | n/a | 422.08% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6475 | 6.16M | -2.76% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.315 | 4.97M | -1.56% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.42 | 3.63M | 1.43% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.751 | 1.10M | 24.54% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 915.21K | -8.33% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.85 | 16.67 | Cheaper |
Ent. to Revenue | 0.95 | 309.37 | Cheaper |
PE Ratio | - | 29.14 | - |
Price to Book | 12.05 | 12.81 | Par |
Dividend Yield | - | 2.80 | - |
Std. Deviation (3M) | 71.40 | 75.12 | Par |
Debt to Equity | -1.48 | -0.93 | Cheaper |
Debt to Assets | 0.91 | 0.45 | Expensive |
Market Cap | 92.15M | 5.22B | Emerging |